Novo and Eli Lilly defend obesity-drug safety as GLP-1 side-effect scrutiny grows
Debate over the broader health effects of blockbuster GLP-1 obesity medicines is intensifying as nutrition concerns add to existing scrutiny of side effects. Novo Nordisk and Eli Lilly are pushing back against fresh claims that poor diet while using the treatments could worsen gut health and immune function.
Highlights
- Novo and Eli Lilly face increased regulatory and legal scrutiny as the FDA orders new warning labels for rare blindness risks and both encounter hundreds of U.S. lawsuits over GLP-1 drugs.
- GLP-1 drugs, generating about $67bn in annual sales for Novo and Lilly, are linked to gastrointestinal side effects, potential nutritional deficiencies, vision loss, and rising hair loss treatment sales.
- Novo's September study of 10,052 people found semaglutide users reduced heart biological age by two to four years compared to placebo, with additional organ benefits noted.
Safety debate widens around GLP-1 treatments
As reported by the Financial Times, the latest criticism comes after Tim Spector, co-founder of the Zoe nutrition app, says at the newspaper's pharma summit this week that users of GLP-1 medicines have “terrible” gut microbiomes, worse than he expected given the drugs’ benefits.Spector says unpublished research by Zoe and academic partners on semaglutide users points to potential concerns, but he later clarifies that it is not yet clear whether the drug itself is responsible, whether the findings reflect lower fibre intake, or where patients started from. He also says the medicines have clear benefits for many people.
Novo says semaglutide has been extensively examined and that it is working closely with regulators to continuously monitor the safety profile of its medicines. Eli Lilly, whose drugs do not use semaglutide, says it actively monitors and reports safety issues, adding that patients experiencing side effects should speak with their healthcare provider.
Regulatory and litigation pressure builds
The exchange adds to a broader industry debate over the risks and benefits of GLP-1 drugs, which have become some of the world's best-selling medicines as demand for obesity treatment surges. While the products are shown to cut weight and reduce the risk of heart disease, they are also linked to stomach problems, vision loss and indirect effects tied to poor nutrition, including tiredness, hair loss and muscle wastage.Doctors with the American Society for Nutrition and others say last year that preventing nutrient deficiencies is critical for GLP-1 patients. Last week, Kimberly-Clark's chief says sales of its Rogaine hair-loss treatment have risen 30 percent so far this year and that the increase may be driven in part by GLP-1 adoption.
Novo and Lilly, which together generate about $67bn in sales from diabetes and obesity drugs last year, are also facing mounting regulatory and legal scrutiny in the U.S. This week, the U.S. Food and Drug Administration orders GLP-1 makers to add warning labels about a rare condition that can lead to permanent blindness in one eye, while both companies already face hundreds of U.S. lawsuits alleging their drugs caused non-arteritic anterior ischaemic optic neuropathy, or Naion.
The companies say patient safety is their top priority and deny a causal link between Naion and their medicines. They also acknowledge common gastrointestinal side effects such as vomiting, nausea and constipation, and rare cases of acute pancreatitis, but reject U.S. litigation alleging more serious gastrointestinal injuries were caused without adequate warning.
Both groups maintain that the benefits of GLP-1s outweigh the risks, and they continue to highlight broader potential uses for the drug class. Research published this year finds obesity-drug users are less likely to suffer from several common addictions, while separate results from Novo and Lilly also explore whether the medicines may help slow biological ageing.
Novo's September analysis of 10,052 people says semaglutide, the active ingredient in Wegovy, reduces heart biological age by about two to four years versus placebo, with additional reductions of one to four years across kidney, brain, pancreas, lung and multiorgan measures.
We have previously detailed CVS GLP-1 pricing and its $350-a-month break-even threshold for employer health plans.